Literature DB >> 8805670

A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity.

J D Spahn1, S J Szefler, W Surs, D E Doherty, S R Nimmagadda, D Y Leung.   

Abstract

We have recently demonstrated that the combination of IL-2 and IL-4 blunts T cell responses to glucocorticoids in steroid resistant (SR) asthma by reducing glucocorticoid receptor (GCR)-binding affinity. Since immune activation appears to be involved in the acquisition of steroid resistance, we sought to identify whether other cytokines could also induce diminished GCR-binding affinity. In the current report, utilizing a [3H]dexamethasone radioligand-binding assay and Scatchard analysis, we found that IL-13, a cytokine with similar actions as IL-4, could induce diminished GCR binding-affinity (GCR Kd = 34.4 +/- 2.3 nM with IL-13 vs Kd = 8.8 +/- 0.7 nM for unstimulated control cells; p < 0.001) in PBMC from normal subjects. In contrast, PBMC incubated with IL-1, IL-3, IL-5, IL-7, IL-8, IL-12, or granulocyte-macrophage-CSF had no effect on GCR-binding affinity; and no additive effect to the decreased GCR-binding affinity was noted when IL-13 was cocultured with IL-2 or IL-4. The cell target of IL-13-induced GCR effects was studied and found to reside in the non-T cell population; specifically, the monocyte fraction. To determine the functional significance of the decreased GCR-binding affinity, monocytes were pretreated with and without IL-1 3 prior to stimulation with LPS and hydrocortisone. IL-13 pretreatment of monocytes significantly diminished (p = 0.005) the suppressive effects of hydrocortisone on LPS-induced IL-6 production. IL-13, by virtue of its ability to induce diminished GCR-binding affinity, may contribute to impaired GC responsiveness during inflammatory illnesses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805670

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Potential Role of Mast Cells in Regulating Corticosteroid Insensitivity in Severe Asthma.

Authors:  Abdulrahman Alzahrani; Aamir Hussain; Fahad Alhadian; Jameel Hakeem; Sana Douaoui; Omar Tliba; Peter Bradding; Yassine Amrani
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.

Authors:  Audreesh Banerjee; Cynthia Koziol-White; Reynold Panettieri
Journal:  Curr Opin Pharmacol       Date:  2012-02-24       Impact factor: 5.547

Review 4.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

Review 5.  Asthma and Corticosteroid Responses in Childhood and Adult Asthma.

Authors:  Amira Ali Ramadan; Jonathan M Gaffin; Elliot Israel; Wanda Phipatanakul
Journal:  Clin Chest Med       Date:  2019-03       Impact factor: 2.878

Review 6.  Proinflammatory Pathways in the Pathogenesis of Asthma.

Authors:  R Stokes Peebles; Mark A Aronica
Journal:  Clin Chest Med       Date:  2019-03       Impact factor: 2.878

Review 7.  Glucocorticosteroids: current and future directions.

Authors:  Peter J Barnes
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 8.  Cytokines and glucocorticoid receptor signaling. Relevance to major depression.

Authors:  Thaddeus W W Pace; Andrew H Miller
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 9.  Interleukin-13: prospects for new treatments.

Authors:  C E Brightling; S Saha; F Hollins
Journal:  Clin Exp Allergy       Date:  2009-10-30       Impact factor: 5.018

10.  Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1.

Authors:  Omar Tliba; Gautam Damera; Audreesh Banerjee; Su Gu; Hasna Baidouri; Stefan Keslacy; Yassine Amrani
Journal:  Am J Respir Cell Mol Biol       Date:  2007-10-18       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.